Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial

References

• Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558–e631.
   PubMed Web of Science ®Google Scholar
• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–770.
   PubMed Web of Science ®Google Scholar
• Cirino AL, Ho C. Hypertrophic cardiomyopathy overview. GeneReviews®. [Internet]: Seattle (WA): University of Washington; 2021.
   Google Scholar
• Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–2239.
   PubMed Web of Science ®Google Scholar
• Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655–668.
   PubMed Web of Science ®Google Scholar
• Cox S, O'Donoghue AC, McKenna WJ, et al. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997;78(2):182–187.
   PubMed Web of Science ®Google Scholar
• Magnusson P, Mörner S, Gadler F, et al. Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators. Health Qual Life Outcomes. 2016;14(1):1–9.
   PubMedGoogle Scholar
• Jacquelinet M, Pentiah AD, Coisne A, et al. Quality of life in outpatients with hypertrophic cardiomyopathy. Arch Cardiovasc Dis Suppl. 2017;9(1):34.
   Google Scholar
• Huff CM, Turer AT, Wang A. Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. Qual Life Res. 2013;22(3):647–652.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769.
   PubMed Web of Science ®Google Scholar
• Maron MS, Ommen SR. Exploring new and old therapies for obstructive hypertrophic cardiomyopathy: mavacamten in perspective. Circulation. 2021;143(12):1181–1183.
   PubMed Web of Science ®Google Scholar
• Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467–2475.
   PubMed Web of Science ®Google Scholar
• Dyer MT, Goldsmith KA, Sharples LS, et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8:13.
   PubMed Web of Science ®Google Scholar
• Batóg P, Rencz F, Péntek M, et al. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. Kardiol Pol. 2018;76(5):860–870.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims [Internet] 2009. [cited August 06 2021]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims
   Google Scholar
• Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109.
   PubMed Web of Science ®Google Scholar
• Ho CY, Olivotto I, Jacoby D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2020;13(6):e006853.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941.
   PubMed Web of Science ®Google Scholar
• Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–1255.
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592.
   PubMed Web of Science ®Google Scholar
• Streiner D, Norman GR, Cairney J. Health measurement scales: a practical guide to their development and use. Vol. 5th ed. New York: Oxford University Press; 2015.
   Google Scholar
• Simpson E, Eckert L, Gadkari A, et al. Validation of the atopic dermatitis control tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):1–10.
   PubMed Web of Science ®Google Scholar
• Hanna M, Damy T, Grogan M, et al. Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial). Am J Cardiol. 2021;141:98–105.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Lucas R, Cowie MR. Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach. ESC Heart Fail. 2019;6(1):3–9.
   PubMed Web of Science ®Google Scholar
• Thomas M, Jones PG, Cohen DJ, et al. Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. Eur Heart J Qual Care Clin Outcomes. 2021;7(4):388–396.
   PubMed Web of Science ®Google Scholar
• Brazier J, Longworth L. NICE DSU technical support document 8: an introduction to the measurement and valuation of health for NICE submissions. Report by the decision support unit. London: National Institute for Health and Care Excellence (NICE); 2011.
   Google Scholar
• Institute for Clinical and Economic Review (ICER). 2020–2023. Value Assessment Framework [Internet]. 2020 Jan 21 [updated 2021 Oct 25; cited 2021 Nov 11]. Available from: https://icer.org/wp-content/uploads/2021/10/ICER_2020_2023_VAF_102521.pdf
   Google Scholar
• Sandtröm A, Sandberg C, Rinnström D, et al. Factors associated with health-related quality of life among adults with tetralogy of fallot. Open Heart. 2019;6(1):e000932.
   PubMed Web of Science ®Google Scholar
• Griffiths A, Paracha N, Davies A, et al. Analyzing health-related quality of life data to estimate parameters for cost-effectiveness models: an example using longitudinal EQ-5D data from the SHIFT randomized controlled trial. Adv Ther. 2017;34(3):753–764.
   PubMed Web of Science ®Google Scholar
• Göhler A, Geisler BP, Manne JM, et al. Utility estimates for decision–analytic modeling in chronic heart failure—health states based on New York heart association classes and number of rehospitalizations. Value Health. 2009;12(1):185–187.
   PubMed Web of Science ®Google Scholar